TY - JOUR

T1 - The eha research roadmap

T2 - normal hematopoiesis

AU - Jaffredo, Thierry

AU - Balduini, Alessandra

AU - Bigas, Anna

AU - Bernardi, Rosa

AU - Bonnet, Dominique

AU - Canque, Bruno

AU - Charbord, Pierre

AU - Cumano, Anna

AU - Delwel, Ruud

AU - Durand, Charles

AU - Fibbe, Willem

AU - Forrester, Lesley

AU - De Franceschi, Lucia

AU - Ghevaert, Cedric

AU - Gjertsen, Bjørn

AU - Gottgens, Berthold

AU - Graf, Thomas

AU - Heidenreich, Olaf

AU - Hermine, Olivier

AU - Higgs, Douglas

AU - Kleanthous, Marina

AU - Klump, Hannes

AU - Kouskoff, Valerie

AU - Krause, Daniela

AU - Lacaud, George

AU - Lo Celso, Cristina

AU - Martens, Joost H.A.

AU - Méndez-Ferrer, Simón

AU - Menendez, Pablo

AU - Oostendorp, Robert

AU - Philipsen, Sjaak

AU - Porse, Bo

AU - Raaijmakers, Marc

AU - Robin, Catherine

AU - Stunnenberg, Henk

AU - Theilgaard-Mönch, Kim

AU - Touw, Ivo

AU - Vainchenker, William

AU - Corrons, Joan Lluis Vives

AU - Yvernogeau, Laurent

AU - Schuringa, Jan Jacob

N1 - Funding Information: WF is a consultant for Glycostem Therapeutics and Starfish Innovations. LF is a consultant for Macomics and Resolution Therapeutics. BG received royalties of payments from Abbvie, Astella, Pfizer, Jazz Pharmaceuticals. OHe received grants from Celgene, BMS, AB science. DK received Research funding from Merck. PM received consultant fees from OneChain Immunotherapeutics. HS received grants from EU HCA|Organoids. KTM was supported by a clinical research fellowship and a center grant from the Novo Nordisk Foundation (grant no. 100191, Novo Nordisk Foundation Center for Stem Cell Biology, DanStem; grant no. NNF17CC0027852, KTM, BP) and by grants from the Danish Council for Strategic Research (grant no. 133100153, KTM), the Danish Cancer Society (grant no. R72-A4572-13-S2, KTM), Børnecancerfonden (2016-0255). WV received patent with a license to Qiagen and research grant from INCYTE. All the other authors have no conflicts of interest to disclose.

PY - 2021

Y1 - 2021

N2 - In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1–2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cell-based Immune Therapies; and Gene Therapy.

AB - In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1–2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cell-based Immune Therapies; and Gene Therapy.

U2 - 10.1097/HS9.0000000000000669

DO - 10.1097/HS9.0000000000000669

M3 - Review

C2 - 34853826

AN - SCOPUS:85120666780

VL - 5

JO - HemaSphere

JF - HemaSphere

SN - 2572-9241

IS - 12

M1 - e669

ER -